Publications by authors named "Juan Fortunato Garcia-Prieto"
Background COVID-19 is an infectious illness, featured by an increased risk of thromboembolism. However, no standard antithrombotic therapy is currently recommended for patients hospitalized with COVID-19. The aim of this study was to evaluate safety and efficacy of additional therapy with aspirin over prophylactic anticoagulation (PAC) in patients hospitalized with COVID-19 and its impact on survival.
View Article and Find Full Text PDFArticle Synopsis
- Most COVID-19 research focuses on hospitalized patients, leaving the impact of prior oral anticoagulation (OAC) therapy before admission understudied.
- Analyzing data from the HOPE COVID-19 Registry, the study compared outcomes between hospitalized patients who had or hadn’t used OAC prior to their admission.
- Results indicated that patients on prior OAC faced a higher risk of mortality and adverse outcomes than those without OAC, with no significant differences between types of OAC used (VKAs vs. DOACs).
Introduction: Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death.
Methods: A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease.
Background: Smoking has been associated with poorer outcomes in relation to COVID-19. Smokers have higher risk of mortality and have a more severe clinical course. There is paucity of data available on this issue, and a definitive link between smoking and COVID-19 prognosis has yet to be established.
View Article and Find Full Text PDFRenin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry.
Am Heart J
July 2021
Background: The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site.
Methods: HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive.